Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16502358 | 0.83 | GRM2 (0.43) | GRM2KDM4ELMNAS1PR4TGFBR1 | |
| SCHEMBL739388 | 0.81 | GRM2 (0.41) | GRM2S1PR4ALDH1A1 | |
| SCHEMBL30059265 | 0.80 | MEN1 (0.40) | KDM4ELMNAPOLBBRD4MEN1 | |
| SCHEMBL25968454 | 0.80 | MEN1 (0.40) | KDM4ELMNAPOLBBRD4MEN1 | |
| SCHEMBL30739301 | 0.78 | MAP4K4 (0.42) | KDM4ELMNAPOLBCASP6MEN1 | |
| SCHEMBL23147096 | 0.78 | AXL (0.41) | KDM4ELMNAPOLBCASP6TGFBR1 | |
| SCHEMBL29811996 | 0.78 | AXL (0.41) | KDM4ELMNAPOLBCASP6TGFBR1 | |
| SCHEMBL25968200 | 0.78 | ALDH1A1 (0.42) | KDM4ELMNAPOLBBRD4KMT2A | |
| SCHEMBL12507130 | 0.77 | GRM2 (0.39) | GRM2S1PR4TGFBR1BRD4MEN1 | |
| SCHEMBL26585989 | 0.77 | ALOX5AP (0.50) | KDM4ELMNAPOLBCASP6ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085577-B2 | 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085577-B2 | 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085577-B2 | 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140200208-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ADDEX PHARMA, S.A. (CH) | 2014-07-17 | — | — | US | disclosed |
| US-20140200208-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ADDEX PHARMA, S.A. (CH) | 2014-07-17 | — | — | US | disclosed |
| US-20140200208-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ADDEX PHARMA, S.A. (CH) | 2014-07-17 | — | — | US | disclosed |
| US-8748621-B2 | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| EP-2200985-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20100099715-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMECEUTICALS, INC (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099715-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMECEUTICALS, INC (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099715-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMECEUTICALS, INC (US) | 2010-04-22 | — | — | US | disclosed |
| EP-2134690-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009033702-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009033702-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008107480-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200208-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRIA2 | GRM2 1/4885KDM4E 1644/4885LMNA 4769/4885 |
| US-20100099715-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR MODULATORS | GRM2, GRIK2, GRM1 | GRM2 1/4885KDM4E 1868/4885LMNA 3650/4885 |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | GRM2, GRM1, GRM3 | GRM2 1/4885KDM4E 1572/4885LMNA 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.